ACTU Stock Overview
A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Actuate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.31 |
| 52 Week High | US$11.73 |
| 52 Week Low | US$5.51 |
| Beta | 0 |
| 1 Month Change | 15.20% |
| 3 Month Change | 46.66% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.74% |
Recent News & Updates
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer
Mar 26Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth?
Feb 12
Shareholder Returns
| ACTU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.7% | -1.0% | -0.3% |
| 1Y | n/a | -10.4% | 11.3% |
Return vs Industry: Insufficient data to determine how ACTU performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ACTU performed against the US Market.
Price Volatility
| ACTU volatility | |
|---|---|
| ACTU Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: ACTU has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACTU's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 10 | Dan Schmitt | actuatetherapeutics.com |
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer.
Actuate Therapeutics, Inc. Fundamentals Summary
| ACTU fundamental statistics | |
|---|---|
| Market cap | US$202.67m |
| Earnings (TTM) | -US$25.31m |
| Revenue (TTM) | n/a |
Is ACTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACTU income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$25.31m |
| Earnings | -US$25.31m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACTU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 08:33 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Actuate Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Christopher Liu | Lucid Capital Markets |